Forest Labs., LLC v. Sigmapharm Labs., LLC
Plaintiff’s testing of representative ANDA products demonstrated literal infringement.
November 16, 2018
Case Name: Forest Labs., LLC v. Sigmapharm Labs., LLC, Civ. No. 14-cv-1119-MSG, 2018 U.S. Dist. LEXIS 195458 (D. Del. Nov. 16, 2018) (Goldberg, J.)
Drug Product and Patent(s)-in-Suit: Saphris® (asenapine maleate); U.S. Patent No. 5,763,476 (“the ’476 patent”)
Nature of the Case and Issue(s) Presented: Forest manufactured Saphris, a sublingual tablet used to treat schizophrenia and other bipolar-related disorders. Sigmapharm filed an ANDA seeking to market a generic version of Saphris. Forest filed suit, alleging infringement of the ’476 patent, which claimed a pharmaceutical composition of Saphris. After a bench trial, the Court concluded that Sigmapharm’s generic product infringed the ’476 patent.
Why Forest Labs Prevailed: At trial, the parties’ dispute focused on a single issue—whether Sigmapharm’s generic product disintegrated “within 30 seconds in water at 37° Celsius.” Forest Labs took a direct approach to proving its case, devising a 30 and 55 second test demonstrating that the generic tablets did, in fact, disintegrate as claimed. The court found the test, and accompanying expert testimony, persuasive and accurate. Accordingly, the court ruled that Sigmapharm infringed the ’476 patent.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.